Literature DB >> 15866565

Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists.

Douglas R Danforth1, Laura K Arbogast, Chad I Friedman.   

Abstract

OBJECTIVE: To examine the effects of GnRH antagonists on preantral follicle survival in vivo and to investigate whether GnRH antagonist use during cyclophosphamide treatment would protect the ovary and preserve primordial follicle survival in a murine model.
DESIGN: Prospective basic research study.
SETTING: Research laboratory in an academic medical center. ANIMAL(S): Adult C57Bl/6 mice (5 to 6 weeks old). INTERVENTION(S): Mice received either a single injection of GnRH agonist (leuprolide acetate) on study day -10 or injections of the GnRH antagonist (antide or cetrorelix) on study days -3 and 0. Some animals also received the chemotherapeutic agent cyclophosphamide on day 0. All animals were killed by CO2 asphyxiation on day 7. To examine direct vs. indirect effects, some mice received GnRH antagonist under the bursa of one ovary, with the contralateral ovary receiving vehicle. Ovaries were fixed in Kahle's solution; 7-mum tissue sections were stained with Lillie's allochrome, and preantral follicles were counted on every fifth section. MAIN OUTCOME MEASURE(S): Numbers of primordial, primary, and secondary follicles. RESULT(S): Systemic administration of both GnRH antagonists caused a significant destruction of primordial follicles compared with control mice. Similar results were obtained whether the antagonists were administered systemically or directly to the ovary. Gonadotropin-releasing hormone agonist had no effect on primordial follicle numbers by itself but reduced the follicular depletion caused by cyclophosphamide. CONCLUSION(S): In contrast to the effects of GnRH agonists to reduce chemotherapeutic destruction of primordial follicles, GnRH antagonists do not protect the ovary from the damaging effects of cyclophosphamide. More importantly, GnRH antagonists alone deplete primordial follicles in this murine model, likely through a direct effect on the ovary. Whether these observations apply to other species requires further study.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15866565     DOI: 10.1016/j.fertnstert.2004.12.030

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  14 in total

1.  Fruitful progress to fertility: preserving oocytes from chemodestruction.

Authors:  Min Xu; Mary Ellen Pavone; Teresa Woodruff
Journal:  Nat Med       Date:  2011-12-06       Impact factor: 53.440

2.  A Combination of a GnRH Antagonist and Agonist for Fertility Preservation in an Adolescent Female Murine Model.

Authors:  Jennifer Flora Knudtson; Marlen Tellez Santos; Courtney M Failor; Peter A Binkley; Jacob P Venesky; Rajeshwar R Tekmal; Randal D Robinson; Robert S Schenken
Journal:  Reprod Sci       Date:  2016-12-14       Impact factor: 3.060

3.  Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in premenopausal women.

Authors:  Hengxi Chen; Li Xiao; Jinke Li; Lin Cui; Wei Huang
Journal:  Cochrane Database Syst Rev       Date:  2019-03-03

4.  Reproductive dysfunction and decreased GnRH neurogenesis in a mouse model of CHARGE syndrome.

Authors:  Wanda S Layman; Elizabeth A Hurd; Donna M Martin
Journal:  Hum Mol Genet       Date:  2011-05-19       Impact factor: 6.150

5.  Granulocyte colony-stimulating factor with or without stem cell factor extends time to premature ovarian insufficiency in female mice treated with alkylating chemotherapy.

Authors:  Malgorzata E Skaznik-Wikiel; Megan M McGuire; Meena Sukhwani; Julia Donohue; Tianjiao Chu; Thomas C Krivak; Aleksandar Rajkovic; Kyle E Orwig
Journal:  Fertil Steril       Date:  2013-02-26       Impact factor: 7.329

6.  Assessment of fertility protection and ovarian reserve with GnRH antagonist in rats undergoing chemotherapy with cyclophosphamide.

Authors:  Claudia N C D Lemos; Fernando M Reis; Guilherme N Pena; Laila C Silveira; Aroldo F Camargos
Journal:  Reprod Biol Endocrinol       Date:  2010-05-18       Impact factor: 5.211

7.  Influence of gonadotropin-releasing hormone agonist on the effect of chemotherapy upon ovarian cancer and the prevention of chemotherapy-induced ovarian damage: an experimental study with nu/nu athymic mice.

Authors:  Qiong-yan Lin; Yi-feng Wang; Hui-nan Weng; Xiu-jie Sheng; Qing-ping Jiang; Zhi-ying Yang
Journal:  J Zhejiang Univ Sci B       Date:  2012-11       Impact factor: 3.066

Review 8.  Hormonal suppression for fertility preservation in males and females.

Authors:  Marvin L Meistrich; Gunapala Shetty
Journal:  Reproduction       Date:  2008-05-30       Impact factor: 3.906

9.  Multiple approaches for individualized fertility protective therapy in cancer patients.

Authors:  I Demeestere; F Moffa; F Peccatori; C Poirot; E Shalom-Paz
Journal:  Obstet Gynecol Int       Date:  2011-12-29

10.  Combination of a GnRH agonist with an antagonist prevents flare-up effects and protects primordial ovarian follicles in the rat ovary from cisplatin-induced toxicity: a controlled experimental animal study.

Authors:  Xiaoyan Li; Xiang Kang; Qingchun Deng; Jing Cai; Zehua Wang
Journal:  Reprod Biol Endocrinol       Date:  2013-03-01       Impact factor: 5.211

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.